Target-specific delivery of doxorubicin to human glioblastoma cell line via ssDNA aptamer

Targeted drug delivery approaches have been implementing significant therapeutic gain for cancer treatment since last decades. Aptamers are one of the mostly used and highly selective targeting agents for cancer cells. Herein, we address a nano-sized targeted drug delivery approach adorned with A-17...

Full description

Saved in:
Bibliographic Details
Published in:Journal of biosciences 2018-03, Vol.43 (1), p.97-104
Main Authors: Bayrac, Abdullah Tahir, Akca, Oya Ercan, Eyidogan, Fusun Inci, Oktem, Huseyin Avni
Format: Article
Language:English
Subjects:
Aptamers
Biomedical and Life Sciences
Biomedicine
Brain cancer
Breast cancer
Cancer
Cell Biology
Cell lines
Cytometry
Cytotoxicity
Deoxyribonucleic acid
DNA
Doxorubicin
Drug delivery
Drug delivery systems
Drugs
Flow cytometry
Glioblastoma
Life Sciences
Microbiology
Plant Sciences
Toxicity
Transport
Tumor cell lines
Tumors
Zoology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Targeted drug delivery approaches have been implementing significant therapeutic gain for cancer treatment since last decades. Aptamers are one of the mostly used and highly selective targeting agents for cancer cells. Herein, we address a nano-sized targeted drug delivery approach adorned with A-172 glioblastoma cell-line-specific single stranded DNA (ssDNA) aptamer in which the chemotherapeutic agent Doxorubicin (DOX) had been conjugated. DNA aptamer, GMT-3, was previously selected for specific recognition of glioblastoma and represented many advantageous characteristics for drug targeting purposes. Flow cytometry analysis proved the binding efficiency of the specific aptamer to tumour cell lines. Cell-type-specific toxicity of GMT-3:DOX complex was showed by XTT assay and terminated cytotoxic effects were screened for both target cell and a control breast cancer cell line. The result of this contribution demonstrated the potential utility of GMT-3 aptamer-mediated therapeutic drug transportation in the treatment of gliomas specifically. It was concluded that aptamer-mediated drug delivery can be applied successfully for clinical use.
ISSN:0250-5991
0973-7138
DOI:10.1007/s12038-018-9733-x